|[June 12, 2014]
Research and Markets: Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/r59ll4/complicated)
has announced the addition of the "Complicated
Intra-Abdominal Infections - Pipeline Review, H1 2014" report
to their offering.
This report provides comprehensive information on the therapeutic
development for Complicated Intra-Abdominal Infections, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
It also reviews key players involved in the therapeutic development for
Complicated Intra-Abdominal Infections and special features on
late-stage and discontinued projects.
Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
The report provides a snapshot of the global therapeutic landscape of
Complicated Intra-Abdominal Infections
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
The report reviews key players involved in the therapeutics
development for Complicated Intra-Abdominal Infections and enlists all
their major and minor projects
The report summarizes all the dormant and discontinued pipeline
Merck & Co., Inc.
Melinta Therapeutics, Inc
Cubist Pharmaceuticals, Inc.
MerLion Pharmaceuticals Pte Ltd
Atox Bio Inc.
Tetraphase Pharmaceuticals Inc.
Biota Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/r59ll4/complicated
[ Back To TMCnet.com's Homepage ]